Martin Leon
Dr. Leon received his medical degree from the Yale School of Medicine and completed his internal medicine internship, residency and cardiology fellowship at the Yale-New Haven Hospital. He is currently a Professor of Medicine at Columbia University’s Center for Interventional Vascular Therapy (CIVT) at New York-Presbyterian Hospital/Columbia University Medical Center and serves on the Executive Board of the New York-Presbyterian/Columbia Heart Valve Center. Marty was previously the Director of Cardiovascular Research and Education at the Lenox Hill Hospital, as well as the Director of Clinical Research at the Washington Cardiology Center.
Marty was the Founder of the Cardiovascular Research Foundation (CRF) in New York City and is currently CRF’s Co-Director of the Medical Research and Education Division. He founded and directed Transcatheter Cardiovascular Therapeutics (TCT), dedicated to interventional cardiovascular medicine, which celebrated its 28th anniversary last year. A distinguished pioneer in interventional cardiovascular medicine, Dr. Leon has been the national Principal Investigator for multiple landmark clinical trials, including STRESS, STARS, Gamma-one, SIRIUS, ENDEAVOR, and, most recently, the PARTNER trial.
Declaration of interest
| Function | Company |
|---|---|
| Information not available at the time of editing |
Latest contributions
The impact of paravalvular leak, permanent pacemaker implantation and the planning for reinterventions on lifetime management in TAVI patients
22 May 2025 – From EuroPCR 2025
How do paravalvular leak, pacemaker implantation and reintervention planning shape lifetime outcomes in TAVI patients?
This session examines these crucial aspects through the case of a 77-year-old male with bicuspid aortic valve stenosis, HFpEF and multiple comorbidities, including diabetes, obesity and sleep apnoea.
Follow the discussion to understand...
Hotline TAVI 1: extended analysis of the randomised trials
21 May 2025 – From EuroPCR 2025
Gain comprehensive insights from extended analyses of randomized TAVI trials. This session reviews five-year UK TAVI outcomes, cardiac damage evolution in asymptomatic aortic stenosis, one-year results from the LANDMARK trial, and three-year comparisons of balloon-expandable valves, highlighting critical clinical implications.
Mitral hotline: new devices
20 May 2025 – From EuroPCR 2025
Stay updated on emerging devices in mitral valve repair and replacement with this session covering novel technologies including transcatheter edge-to-edge repair (TEER), posterior leaflet restoration, transfemoral mitral annuloplasty, and a first-in-human transseptal TMVR system. Clinical trial data and early feasibility experiences provide valuable insights into advancing...
Sirolimus coated balloon for coronary artery disease and peripheral artery disease treatment: the new frontier
20 May 2025 – From EuroPCR 2025
This EuroPCR 2025 session delivers a comprehensive update on the MagicTouch sirolimus-coated balloon (SCB) and its expanding role in treating both coronary and peripheral artery disease (CAD/PAD). The session covers the extensive clinical trial program supporting MagicTouch as a versatile treatment option across multiple indications. It...
Asymptomatic severe aortic stenosis: Will these trials change my practice?
16 May 2024 – From EuroPCR 2024
This session, in collaboration with Partners in Learning, explores the emerging evidence on the use of transcatheter aortic valve implantation (TAVI) in patients with asymptomatic severe aortic stenosis. It covers data from registries and randomized controlled trials, the current guideline recommendations, and the potential impact of...
Major Late-Breaking Trials from EuroPCR 2024
15 May 2024 – From EuroPCR 2024
This session presents the latest results from major late-breaking trials presented at EuroPCR 2024. It covers a one-month DAPT followed by 5-month ticagrelor monotherapy in acute coronary syndromes with DCB, the first TAVI vs. SAVR randomised trial in younger low-risk patients with severe tricuspid or bicuspid...
TEER for primary mitral regurgitation - LIVE case
15 May 2024 – From EuroPCR 2024
A 76-year-old male, with previous CABG in 2015, hypertension, diabetes, and pulmonary hypertension (WHO2), presented with severe symptomatic primary MR (P3 flail).
The operators implanted 1 MitraClip (XTW) step-by-step, from the transseptal puncture to the closure, guided by TEE echo and under general anaesthesia, via the venous...
Tribute to Alain Cribier
14 May 2024 – From EuroPCR 2024
Asymptomatic severe aortic stenosis, how will new evidence change our practice?
15 May 2024 – From EuroPCR 2024
Victoria Delgado and Martin Leon discuss how to treat patients with asymptomatic severe aortic stenosis at an earlier stage and how current trials may change our practice in the future and broaden the indications.
This interview was filmed at EuroPCR 2024: see more videos here.
First report of an IDE pivotal study of a dedicated splitting device during TAVR
15 May 2024 – From EuroPCR 2024
Watch this interview in which Christopher Cook hosts Martin Leon to discuss pivotal study data on the ShortCut dedicated leaflet splitting device. They revisit the unmet clinical need for leaflet splitting during TAVR: transcatheter valve failures, noting that transcatheter valve failures could surpass surgical bioprosthetic valve failures...
PARTNER 3 Low-Risk trial: 5-year insights on TAVI vs. SAVR outcomes
Alex Sticchi interviews Martin Leon about the five-year clinical and echocardiographic outcomes from the PARTNER 3 Low-Risk randomized trial, presented at the #TCT23 Congress.
The analysis reveals comparable outcomes for TAVI and SAVR, with nuanced differences favouring each approach. Prof. Leon emphasizes the importance of long-term data...
TAVI: From simple to complex - LIVE case
20 Nov 2023 – From PCR London Valves 2023
This session explores two clinical cases, providing valuable insights into the essential components of a straightforward and efficient TAVI procedure. Find out more about the application of innovative devices to broaden the scope of aortic valve intervention, facilitating their integration into Heart Team discussions and daily...
Top Innovations
20 Nov 2023 – From PCR London Valves 2023
Discover the future of cardiac care with these 3 top innovations! ARTERY, revolutionizing structural heart treatment, Vesalius Transfemoral DMR Repair, combining chordal and annular support in one-transfemoral device, and Approxima, a right ventricular reshaping device, offering a fresh perspective on tricuspid regurgitation.
!!!NEWSFLASH!!! Long-term outcomes of the TAVI low risk trials - from headlines to clinical practice
20 Nov 2023 – From PCR London Valves 2023
Join this session to navigate through the long-term outcomes of TAVI low-risk trials (Partner 3, Evolut Low Risk...), to enhance your ability to synthesize and interpret clinical evidence and to learn how to seamlessly integrate these insights into your Heart Team's daily clinical practice.
A problem and a solution: aortic regurgitation and the Trilogy TAVI valve
19 Nov 2023 – From PCR London Valves 2023
Consult this session if you want to understand the challenges of imaging for aortic regurgitation and how it can lead to underdiagnosis. Discover the data from the ALIGN-AR trial studying TAVI in aortic regurgitation patients, and learn about the Trilogy valve and the future of TAVI...
Second time TAVI (TAV-in-TAV) - Not as simple as it looks
19 Nov 2023 – From PCR London Valves 2023
Although it is still rare, TAV-in-TAV is likely to become more frequent, as TAVI is increasingly implanted in younger patients. Harmonizing data in this area will therefore help to improve outcomes, the quality of which depends on site experience, bearing in mind that for the time...
Integrating FFRangio into your daily practice - Empowering wire-free insights
18 May 2023 – From EuroPCR 2023
In this session, dive into the world of FFRangio, from concept to clinical reality, and then analyze different cases in real practice to see how useful the physiology is, to try to understand why it is still so little used, and to learn how FFRangio could...
Cutting-edge technologies: clinical updates on TES, BRS, TAVR and LAA closure
17 May 2023 – From EuroPCR 2023
Watch this session to find out more about the three-year outcomes of the FUTURE-II Trial, the TARGET clinical trial roadmap, the TARGET IV NA Trial update, the twelve-month outcomes of the SAVE PROTECT Trial, and the quantitative aortographic assessment of regurgitation in patients treated with VitaFlow.
Defining together the ideal TAVI platform of the future
16 May 2023 – From EuroPCR 2023
How to successfully plan and access a TAVI procedure using ultrasound guidance? How to close a TAVI procedure using suture-based vessel closure devices? How to manage vascular complications during and after TAVI procedures? Join the speakers in this brainstorming session and imagine what tomorrow's ideal TAVI...
Going down the road of coronary artery disease treatment: sirolimus-coated balloon and DES + DCB stent platform
16 May 2023 – From EuroPCR 2023
What better way to talk about sirolimus-coated balloons than with real-life clinical cases? In this session, study the case of a 78-year-old man with crescendo angina and inferior wall ischaemia, or a 48-year-old woman with crescendo angina, type 2 DM and anterior wall hypokinesia with mild...
TAVI in patients with long-life expectancy - LIVE case
16 May 2023 – From EuroPCR 2023
Watch the case of a 75-year-old male patient with history of TIA, symptomatic severe aortic stenosis with RBBB, and preserved LV function. The heart team's decision was to perform TAVI with PCI on LAD a few days before procedure.
First, a cerebral protection device (Sentinel) was implanted....
Welcome introduction
15 May 2023 – From PCR Innovators Day 2023
What else will become the "Next Big Thing" in Coronary Artery Disease, Peripheral Vascular, treatment of Hypertension or Cardiovascular Imaging for the Interventional Cardiologist?
15 May 2023 – From PCR Innovators Day 2023
Mitral - Late-Breaking Trials and Innovations
28 Nov 2022 – From PCR London Valves 2022
Consult this session to discover a selection of late-breaking trials presented during PCR LV 2022: TENDyne European expeRience registry, CLASP IID trial, EXPAND G4, and much more!
TAVI is a mature procedure: implications for lifelong management of young and old patients
27 Nov 2022 – From PCR London Valves 2022
Take a look at these presentations to learn more about TAVI implications for lifelong management, to understand what is happening in the field of aortic valve intervention and to appreciate the evidence governing the application of this procedure in the lifetime journey of patients with aortic...
Twenty years of progress - What we have achieved - LIVE case
27 Nov 2022 – From PCR London Valves 2022
- Part 1: TAVI by axillary access (Live)
An 80-year-old female with peripheral arterial disease presents a symptomatic severe aortic stenosis with small annulus and preserved LV function.
The operators implant, by axillary access, an Evolut pro 26 mm, on general anaesthesia, with predilatation (Balloon 18 mm) and post-dilatation...
Transcatheter tricuspid valve interventions: the future
23 Nov 2021 – From PCR London Valves 2021
In this PCR London Valves 2021 session, observe the case of an 84-year-old, not overweight, quite active, female patient with a past history of restrictive cardiomyopathy and permanent atrial fibrillation, who presented with worsening dyspnea and obvious clinical signs of right ventricular heart failure, and discuss the...
TAVI: the future
22 Nov 2021 – From PCR London Valves 2021
This session from PCR London Valves 2021 particularly focuses on the expected expansions of TAVI to patients at a younger age and with a longer life expectancy, including a virtual live case from Clinique Pasteur, Toulouse, France.
Aortic valve disease: guidelines and beyond
22 Nov 2021 – From PCR London Valves 2021
Through this PCR London Valves 2021 session, compare the new ESC aortic valve disease guidelines with the US guidelines, focus on controversies and uncertainties of these AVD guidelines, see how to apply the guidelines using the Heart Team decision-making concept, and appreciate in a live case...
Aortic valve disease: state-of-the-art
22 Nov 2021 – From PCR London Valves 2021
This PCR London Valves 2021 session begins with important updates on the seminal trials that have defined our TAVI era over the past decade before moving on to new studies that are very likely to shape the evolution of TAVI in the next ten years.
